Cancer vaccines: Clinical development challenges and proposed regulatory approaches for patient access to promising treatments

Cancer

Volumn 112, Issue 5, 2008, Pages 955-961

  Stebbing, Justin ^a,i   Wood, Christopher ^b   Atkins, Michael ^c   Bukowski, Ronald ^d   Litwin, Stephen ^e   Bower, Mark ^f   Parsa, Andrew ^g   Levitsky, Hyam ^h  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

^e Biologics Consulting Group   (United States)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; LIPONOVA; PLACEBO; PROVENGE; SIPULEUCEL T; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VITESPEN;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROL GROUP; DISEASE COURSE; DISEASE FREE SURVIVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

CANCER VACCINES; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; HEALTH SERVICES ACCESSIBILITY; HUMANS; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 39749132274     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23273     Document Type: Note

References (76)